Affiliation:
1. Clinical College of Traditional Chinese Medicine Hubei University of Chinese Medicine Wuhan China
2. Institute of Liver Diseases, Hubei Key Laboratory of Theoretical and Applied Research of Liver and Kidney in Traditional Chinese Medicine Hubei Provincial Hospital of Traditional Chinese Medicine Wuhan China
3. Institute of Liver Diseases Hubei Province Academy of Traditional Chinese Medicine Wuhan China
4. CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology Chinese Academy of Sciences Beijing China
Abstract
AbstractLiver disease represents a significant global burden, placing individuals at a heightened risk of developing cirrhosis and liver cancer. Viral infections act as a primary cause of liver diseases on a worldwide scale. Infections involving hepatitis viruses, notably hepatitis B, C, and E viruses, stand out as the most prevalent contributors to acute and chronic intrahepatic adverse outcome, although the hepatitis C virus (HCV) can be effectively cured with antiviral drugs, but no preventative vaccination developed. Hepatitis B virus (HBV) and HCV can lead to both acute and chronic liver diseases, including liver cirrhosis and hepatocellular carcinoma (HCC), which are principal causes of worldwide morbidity and mortality. Other viruses, such as Epstein–Barr virus (EBV) and cytomegalovirus (CMV), are capable of causing liver damage. Therefore, it is essential to recognize that virus infections and liver diseases are intricate and interconnected processes. A profound understanding of the underlying relationship between virus infections and liver diseases proves pivotal in the effective prevention, diagnosis, and treatment of these conditions. In this review, we delve into the mechanisms by which virus infections induce liver diseases, as well as explore the pathogenesis, diagnosis, and treatment of liver diseases.This article is categorized under:
Infectious Diseases > Biomedical Engineering
Reference102 articles.
1. Hepatocellular carcinoma
2. Vera G. Amandeep K. Krishna K. Saifuddin K. Joyeta D. Jacob V. &Anadi M.(2023).Hepatitis B surface antigen loss rate and safety and discontinuations with pegylated interferon alpha in chronic hepatitis B virus infection a systematic review. The International Liver Congress™EASL European Association for the Study of the Liver June 21‐24 2023.https://www.natap.org/2023/EASL/EASL_105.htm
3. Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy